Stopping Retatrutide: What Happens to Your Weight and Appetite

After stopping retatrutide, weight starts coming back, and sooner than most people expect. In the Phase 2 liver-fat substudy, people had already regained some weight at a check 4 weeks after their last dose (Nature Medicine, 2024). No retatrutide trial has published how much returns over a full year, so the closest guide is tirzepatide: in SURMOUNT-4, people switched to placebo gained 14.0% over 52 weeks, measured from their weight at the switch, while those who stayed on lost another 5.5% (JAMA, 2024). Nobody has tested a taper, and no trial report we read describes withdrawal symptoms beyond appetite returning.

As of October 2026, six Phase 3 trials have reported results and no approved version of retatrutide exists yet. None of them has published a stopping result, so every number below comes either from Lilly's trials or from two approved drugs that work on some of the same hormones. We say which is which each time. For the wider picture of what people lose on the drug, start with the retatrutide weight loss results.

What happens to your weight after stopping retatrutide

The retatrutide-specific evidence is thin, and it points one way. In the first human study, weight stayed down for up to 43 days after a single injection (Cell Metabolism, 2022). So the drug doesn't switch off the day you skip a shot.

It doesn't hold forever either. The liver substudy of the Phase 2 trial followed 98 adults for 48 weeks; those on 12 mg lost 25.9% of their weight. Then everyone stopped. At the safety visit 4 weeks later, the authors saw "some weight regain." The text of the paper puts no number on it.

TRIUMPH-1 shows a small version of the same problem. The headline 28.3% loss on 12 mg is Lilly's efficacy estimand, which assumes everyone stayed on the drug for 80 weeks without other weight treatments. The primary analysis in NEJM counts everyone who was randomized, whether or not they kept taking it, and the figure there is 25.0%. Neither Lilly's release nor the NEJM abstract says how much of that 3.3-point gap is regain after stopping.

What the withdrawal trials found

Two approved drugs have been through proper withdrawal trials, where people who'd lost weight were randomly split between staying on the drug and a switch to placebo. Both point the same way. That's semaglutide and tirzepatide data, not retatrutide.

The plus figures are percent change from the weight at the split, which is easy to misread. Here's what SURMOUNT-4's averages mean for one person. Start at 250 lb and lose 20.9%, and you're at about 198 lb. A 14.0% gain from there adds about 28 lb, which puts you near 225 lb. That's a little over half of the lost weight back within a year, and still about 25 lb below where you began.

The spread matters as much as the average. In SURMOUNT-4, only about 1 in 6 people switched to placebo (16.6%) kept at least 80% of their loss, against 89.5% of those who stayed on tirzepatide. The STEP 1 authors put their result more bluntly: a year after stopping semaglutide and the trial's lifestyle program, people had regained two-thirds of the weight they'd lost.

Retatrutide adds a third hormone, glucagon. The idea that it raises energy use comes from studies that weren't done in people, and nobody has shown it changes what happens after stopping. To see the loss you'd expect on each dose, use the weight loss calculator, and assume part of that number lasts only as long as you keep taking it.

How long does reta last after stopping?

Retatrutide's half-life is about 6 days, measured in the Phase 1b trial (The Lancet, 2022). Half the drug is gone in about a week, and by our math roughly 4% is left 4 weeks after the last shot. The half-life page has the rest of the decay math, including how long a 12 mg level takes to fall to the 2 mg starting level.

Appetite comes back before the drug is fully gone. The liver substudy saw regain at 4 weeks, when a small fraction of the drug was still around. Reddit threads about stalls and about coming off retatrutide often mention appetite returning. Those are reports, not measurements.

Other numbers drift back too. The Zepbound label reports what happened in SURMOUNT-4's placebo group between the switch and week 88: waist size went back up 7.8 cm after dropping 17.8 cm, systolic blood pressure rose 8.2 mmHg after falling 11.2, and pulse fell 5.2 beats per minute after rising 5.0 on the drug. HbA1c rose 0.3 points, in people without diabetes. That's tirzepatide data. Retatrutide raises heart rate too: in the Phase 2 trial, the dose-related rise peaked at 24 weeks and then eased (NEJM, 2023). Nobody has published what it does after stopping.

If you have type 2 diabetes, talk to your doctor before your last dose. The Zepbound label tells prescribers to consider lowering insulin or sulfonylurea doses on tirzepatide, so if yours were cut, blood sugar can climb once the drug stops.

Should you taper off retatrutide?

No trial has tested a retatrutide taper. SURMOUNT-4 and STEP 4 both switched people straight to placebo, and neither the Zepbound nor the Wegovy prescribing information includes a taper schedule (we searched both labels on October 31, 2026). With a 6-day half-life, the level already falls gradually after the last shot.

The closest thing to a step-down test is TRIUMPH-6 (below). One group moves from "dose 1" to "dose 2" after 80 weeks, and the registry doesn't say whether dose 2 is lower.

Reddit has threads on tapering, with people asking whether to space shots out or step the dose down before quitting. None of it has been tested. Our read: a slow step-down might spread the regain out, but nothing here suggests it changes where weight ends up, since in both randomized withdrawal trials the placebo group weighed more at the end than at the split.

Questions to ask before your last shot

No retatrutide stopping plan exists to hand you, so here are the questions this page's data raise for your prescriber.

• If I take insulin or a sulfonylurea, or my blood pressure medicine was cut while I lost weight, what changes after the last dose?
• What's my plan for appetite in the first 2 to 4 weeks, when the drug is still around but hunger may already be back?
• Do I step down first or stop outright? The withdrawal trials stopped outright.
• If I restart, do I start at the bottom again, as the Wegovy label does after 2 or more missed weekly doses?

Do you need to take a break from retatrutide?

No trial has built in breaks, and nothing in the data suggests the body needs one. The Phase 3 obesity trials dosed weekly for 68 to 80 weeks, and TRIUMPH-1's extension ran to 104 weeks. Among the 532 people who continued, the group that began on 12 mg averaged 30.3% below its starting weight (efficacy estimand). Those 532 had all finished 80 weeks on the drug without stopping or cutting their dose, so they're the people for whom it was working and tolerable. Lilly's release on the Phase 2 paper quoted the lead investigator saying people hadn't reached a weight plateau when that study ended at 48 weeks.

So when does reta stop working? In the trials, it didn't while people kept taking it. Loss does slow down: in the Phase 2 trial, the 12 mg group was 17.5% lighter at 24 weeks and 24.2% lighter at 48 weeks (NEJM, 2023), so the second 24 weeks added far less than the first. The retatrutide plateau page covers how to tell a normal slowdown from a problem, and the weight loss timeline shows where in the course it tends to happen.

A break has a known cost. In every withdrawal trial above, weight started back up once the drug stopped. Reddit threads on breaks and restarting are common, but no trial has tested on-off cycles.

Stopping and starting again

You can restart, but going straight back to your old dose after weeks off is close to starting high, and the trials avoided that on purpose. Every TRIUMPH obesity trial started people at 2 mg and stepped up every 4 weeks, with 12 mg reached at week 16 (see the dosage guide and the starting dose page for the full steps). In the Phase 2 trial, 60.0% of people on 8 mg who started at 4 mg had nausea, against 17.1% who started at 2 mg (ClinicalTrials.gov results).

No retatrutide label exists, so there's no official restart rule. The approved drugs give two answers. The Zepbound label covers a single missed dose: take it within 4 days, or skip it and carry on. The Wegovy label goes further: after 2 or more missed weekly doses in a row, it tells prescribers to restart the dose steps at a lower dose, to cut the risk of stomach side effects. That's class guidance to take to your prescriber, not a retatrutide protocol.

A break is also when people switch vials, and a new batch adds its own unknowns. Anything sold as retatrutide for sale online isn't Lilly's product, and when Australia's TGA tested one such vial in 2026, it contained no retatrutide at all, and undeclared semaglutide at about 8 times the level in approved products.

When stopping is the right call

Plenty of people in the trials stopped because of side effects. In TRIUMPH-1, 11.3% of people on 12 mg quit for that reason over 80 weeks, against 4.9% on placebo. In TRIUMPH-4, it was 18.2% on 12 mg against 4.0%, and Lilly says some of those stopped because they felt they were losing too much weight. In the head-to-head TRANSCEND-T2D-2 trial in type 2 diabetes, 4.8% on 9 mg and 7.9% on 12 mg stopped for side effects over 80 weeks, against 2.7% on Ozempic 2 mg (Lilly, October 28, 2026). The side effects guide covers which ones fade and which don't.

Pregnancy is another reason. No one has set a retatrutide number, but the Wegovy label says to stop semaglutide at least 2 months before a planned pregnancy because of its long half-life, and the Zepbound label says to stop when a pregnancy is recognized. The pregnancy and fertility page covers what's known for retatrutide.

What nobody knows yet

The first real answer on stopping retatrutide will come from TRIUMPH-6. About 643 adults with obesity take retatrutide for 80 weeks, then are split three ways for 36 weeks: dose 1, dose 2 or placebo. One of its measures is the share of the week-80 weight loss still kept at week 116. As of October 2026, the trial is no longer recruiting and its primary completion date is estimated for April 2028.

Until then, the questions people ask most have no retatrutide data behind them: how much comes back, how fast, whether a lower maintenance dose holds the loss, and whether a taper helps. Outside Lilly's trials and its single-patient expanded access program, nobody gets retatrutide from a prescriber, because no approved version exists. Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026. The FDA approval page tracks it. Meanwhile, what stopping has done to other people's results is a running topic in Reddit threads on retatrutide, read as reports rather than evidence.